Cancer discovery
-
Although the addition of dasatinib to letrozole improved progression-free survival in postmenopausal women with estrogen receptor-positive, HER2-negative metastatic breast cancer compared with letrozole alone, the clinical benefit was the same for both groups.
-
In a phase I trial of endoxifen, a metabolite of tamoxifen, multiple patients with estrogen receptor-positive breast cancer that was resistant to treatment with aromatase inhibitors had partial responses or long-lasting stable disease.